Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
Mühl
Diána
D
Department of Anaesthesia and Intensive Care, University of Pécs, Ifjúság u.13, 7624 Pécs, Hungary. drdianamuhl@gmail.com
Ghosh
Subhamay
S
Uzuelli
Juliana A
JA
Lantos
János
J
Tanus-Santos
Jose E
JE
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000150:complications / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects* / Q000379:methods; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D055815:Young Adult
D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9